BioNexus Gene Lab (BGLC) Total Current Liabilities (2018 - 2026)

BioNexus Gene Lab (BGLC) has 9 years of Total Current Liabilities data on file, last reported at $796470.0 in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 48.96% year-over-year to $796470.0; the trailing twelve-month figure through Mar 2026 stood at $796470.0 (down 48.96% YoY), and the FY2025 full-year result was $520957.0, down 73.3% from the prior year.
• Total Current Liabilities climbed to $796470.0 in Q1 2026, from $520957.0 in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $2.0 million in Q4 2022 to a low of $520957.0 in Q4 2025.
• A 5-year average of $1.5 million and a median of $1.6 million in 2023 frame the typical range for Total Current Liabilities.
• Peak annual rise in Total Current Liabilities reached 25.62% in 2025, while the deepest fall reached 73.3% in 2025.
• Tracing BGLC's Total Current Liabilities over 5 years: stood at $2.0 million in 2022, then dropped by 18.62% to $1.6 million in 2023, then gained by 19.64% to $2.0 million in 2024, then sank by 73.3% to $520957.0 in 2025, then jumped by 52.89% to $796470.0 in 2026.
• Business Quant data shows BGLC's Total Current Liabilities at $796470.0 in Q1 2026, $520957.0 in Q4 2025, and $678023.0 in Q3 2025.